Humidifiers are sometimes seen as a way to combat allergies and the symptoms of colds and the flu – but in reality many can do quite the opposite,” says James Dyson. “The majority are a breeding ground for nasty germs, which are then distributed around your home.” Dyson claims its humidifier eliminates 99.9 percent of bacteria by exposing every drop of water to ultraviolet light twice before it reaches your lungs.
Idea: Every Ebola confirmed Ebola patient is attached to a dialysis machine that has a glass tube/opening to expose their blood to UV radiation.
If UV kills bacterial and viral pathogens on surfaces can it do the same to viruses in blood assuming it does not damage healthy blood cells.
A procedure that requires minimal research and easy to implement NOW! NO dangerous or untested GMO/vaccines
The particular mechanism with which the body naturally breaks down and prevents infection from lethal infections including Ebola, HIV, HCV and SARS has gradually emerged. The mechanism is called mannose-binding lectins.
Mannose-binding lectins are apparently produced in the human body via a DNA sequence, called the MBL2. When this part of our genes is in order, the body will produce and release these mannose-binding lectins into the bloodstream.
This brings us to the fun part. Yes, humans aren’t the only critters that produce mannose-binding lectins. Red algae also produce these profusely, which allow the algae to protect themselves from invasion by viruses.
The most promising form of mannose-binding lectins is a component of the Scytonema varium red algae called Scytovirin. The protein extract was isolated by researchers from the National Cancer Institute at Frederick, Maryland in 2003. The protein contains 95 amino acids, and was found to bind to HIV-1 viral shells.
As modern medical researchers continually strive for isolated and synthesized versions of nature able to be patented, recombinant versions of Griffithsin were eventually produced using Nicotiana benthamiana plants (a relative of the tobacco plant). These plants were genetically modified so they would produce the same mannose-binding lectins
The main thing holding back large-scale development of effective treatments and vaccines for Ebola to this point is the fact that the return on investment of doing so – the saving of human lives aside – has been a challenging one for private industry to wrap its head around. For one, there’s no chance of a Lipitor-like success. There is no retail market for such drugs, just as there wasn’t for pandemic flu vaccine in 2009. What’s more, governments and non-governmental organizations are pretty much the only buyers around
“Once the government gets into this business, it’s responsible for maintaining what they call ‘warm capacity’,” Kantor says. “Hypothetically, if they want to stockpile 2 million doses of vaccine with the ability to scale to 20 million, they can’t buy the drug once and let the company go bankrupt.” It’s always going to be harder for drug companies to convince themselves of the relative merits of investing in a once-every-fifteen-years virus like Ebola versus funding research into lowering cholesterol levels. But from this point forth, there’s a market for Ebola drugs.
By Michelle Fay Cortez and Jason Gale – February 24, 2009 16:20 EST
The virus material was supposed to contain a seasonal flu virus and was contaminated after “human error”